381 related articles for article (PubMed ID: 34393104)
21. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
23. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.
Vilela VS; Maretti GB; Gama LM; Costa CH; Rufino RL; Levy RA
Rev Bras Reumatol Engl Ed; 2016; 56(5):458-463. PubMed ID: 27692396
[TBL] [Abstract][Full Text] [Related]
24. Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years.
Farah Z; Ali S; Price-Kuehne F; Mackworth-Young CG
Biologics; 2016; 10():59-66. PubMed ID: 27069354
[TBL] [Abstract][Full Text] [Related]
25. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
Kondo N; Fujisawa J; Endo N
Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
[TBL] [Abstract][Full Text] [Related]
26. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
Arnold MB; Khanna D; Denton CP; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE; Pope JE
Rheumatology (Oxford); 2018 Jan; 57(1):152-157. PubMed ID: 29077900
[TBL] [Abstract][Full Text] [Related]
27. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
Abdulkader OAF; Qushmaq K; Aljishi F
Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
[TBL] [Abstract][Full Text] [Related]
28. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.
Agostini E; De Luca G; Bruni C; Bartoli F; Tofani L; Campochiaro C; Pacini G; Moggi-Pignone A; Guiducci S; Bellando-Randone S; Shoenfeld Y; Dagna L; Matucci-Cerinic M
Autoimmun Rev; 2021 Dec; 20(12):102981. PubMed ID: 34718166
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis.
Tang R; Yu J; Shi Y; Zou P; Zeng Z; Tang B; Wang Y; Ling G; Luo M; Xiao R
Int Immunopharmacol; 2020 Jun; 83():106389. PubMed ID: 32172205
[TBL] [Abstract][Full Text] [Related]
31. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
[TBL] [Abstract][Full Text] [Related]
32. Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.
Keystone EC; Anisfeld A; Ogale S; Devenport JN; Curtis JR
J Rheumatol; 2014 Feb; 41(2):216-26. PubMed ID: 24429164
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience.
Henrique-Neto Á; Vasconcelos MYK; Dias JBE; de Moraes DA; Gonçalves MS; Zanin-Silva DC; Zucoloto TG; de Oliveira MFC; Dotoli GM; Weffort LF; Leopoldo VC; Oliveira MC
Adv Rheumatol; 2021 Feb; 61(1):9. PubMed ID: 33549135
[TBL] [Abstract][Full Text] [Related]
35. Effect of menopause on the modified Rodnan skin score in systemic sclerosis.
Vinet É; Bernatsky S; Hudson M; Pineau CA; Baron M;
Arthritis Res Ther; 2014 Jun; 16(3):R130. PubMed ID: 24957704
[TBL] [Abstract][Full Text] [Related]
36. Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial.
Ebata S; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Yoshihide A; Yoshizaki A; Sato S
Rheumatology (Oxford); 2022 Nov; 61(11):4364-4373. PubMed ID: 35136981
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
38. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
Kremer JM; Rigby W; Singer NG; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
Arthritis Rheumatol; 2018 Aug; 70(8):1200-1208. PubMed ID: 29575803
[TBL] [Abstract][Full Text] [Related]
39. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.
Melsens K; Vandecasteele E; Deschepper E; Badot V; Blockmans D; Brusselle G; De Langhe E; De Pauw M; Debusschere C; Decuman S; Deroo L; Houssiau F; Lenaerts J; Piette Y; Thevissen K; Vanthuyne M; Westhovens R; Wijnant S; De Keyser F; Smith V
Acta Clin Belg; 2018 Apr; 73(2):119-125. PubMed ID: 28891418
[TBL] [Abstract][Full Text] [Related]
40. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
Kivitz A; Olech E; Borofsky MA; Zazueta B; Navarro-Sarabia F; Radominski SC; Merrill JT; Pacheco-Tena C; Pei J; Nasmyth-Miller C; Pope JE
J Rheumatol; 2018 Apr; 45(4):456-464. PubMed ID: 29247149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
